Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems Q3 Profit Slides as Sequencer Sales Nosedive; Mass Spec a Bright Spot

NEW YORK, April 25-Applied Biosystems said today that its earnings per share in the third quarter of fiscal 2002 had slid, pulled down in part by sharply slowed demand for sequencing products and equipment.


For the quarter ended March 31, net income for the Applied Biosystems Group was $49.1 million, representing earnings per share of $0.23. For third quarter 2001, net income was $57.7 million, and earnings per share were $0.26.


It has been a "very challenging" time for the company, said Applied Biosystems President Michael Hunkapiller.


Much of the weakness, he said, was attributable to slowed demand for DNA sequencers and sequencing products.


Sales in this segment slipped from $550 million in the first three quarters of fiscal year 2001 to $455 million in the same period this year. This division now counts for only 38 percent of the company's revenue, down from 46 percent in the third quarter of 2001.


Revenues from sequencing instrument sales slumped 35 percent. Sales of the ABI 3700 alone plummeted by 61 percent.


Consumables revenues slid 6 percent for this quarter compared to the equivalent period last year, mostly due to lowered demand from the company's six biggest customers, including Celera Genomics and the Japanese Millennium Project.


"I've revised what makes me happy," said Applera CEO Tony White.


Hunkapiller and White blamed National Institutes of Health funding delays, an uncertain business climate, and weakness in the pharmaceutical market.


Bright spots included a small increase in sales of the company's Sequence Detection System instruments, which climbed by about 5 percent over the third quarter of last fiscal year. Hunkapiller said that during the last nine month period, revenues from this section were up 23 percent over the equivalent period during the previous year.


Mass spectrometry instrument sales were up by 28 percent, led by sales of the API 4000 LC/MS/MS .


Revenues from sources like service contracts, royalties, licenses, and contract research increased 14 percent from $51.6 million in Q3 last year to $58.6 million in Q3 this year.


Hunkapiller said that the company hoped the recent introduction of two high-end second-generation sequencers and mid-range 3100 Avant instruments will help nudge up sequencing instrument sales.


Forecasts for the company's fourth quarter revenue were revised downward to "flat to slightly positive growth," said Chief Financial Officer Dennis Winger. Earnings per share were projected at between $0.18 and $0.21.


Revenue growth for fiscal 2003 is anticipated to be in the high single digits to low teens.


"The change in guidance going forward is a reflection of what's happening currently," said White. "We were surprised to see the basic weakness in our marketplace, we thought it prudent to not create expectations for the Street going forward."


"We think we'll grow next year," he added. "We're coming back, just not the way I'd hoped."


Hunkapiller and White said that the company will hope to see strong growth in the new assay-on-demand service and in SDS instrumentation and services. Mass spectrometry instrument sales are also expected to remain strong.


"We've believe that our whole applied genomic assays business has the potential of becoming the largest part of our overall business," said Hunkapiller.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.